<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="cfr.xsl"?>
<CFRGRANULE xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="CFRMergedXML.xsd">
  <FDSYS>
    <CFRTITLE>21</CFRTITLE>
    <CFRTITLETEXT>Food and Drugs</CFRTITLETEXT>
    <VOL>5</VOL>
    <DATE>2000-04-01</DATE>
    <ORIGINALDATE>2000-04-01</ORIGINALDATE>
    <COVERONLY>false</COVERONLY>
    <TITLE>Requirement for an IND.</TITLE>
    <GRANULENUM>312.20</GRANULENUM>
    <HEADING>Section 312.20</HEADING>
    <ANCESTORS>
      <PARENT HEADING="Title 21" SEQ="4">Food and Drugs</PARENT>
      <PARENT HEADING="CHAPTER I" SEQ="3">FOOD AND DRUG ADMINISTRATION,DEPARTMENT OF HEALTH AND HUMAN SERVICES-Continued</PARENT>
      <PARENT HEADING="SUBCHAPTER D" SEQ="2">DRUGS FOR HUMAN USE</PARENT>
      <PARENT HEADING="PART 312" SEQ="1">INVESTIGATIONAL NEW DRUG APPLICATION</PARENT>
      <PARENT HEADING="Subpart B" SEQ="0">Investigational New Drug Application (IND)</PARENT>
    </ANCESTORS>
  </FDSYS>
  <SECTION>
    <SECTNO>§ 312.20</SECTNO>
    <SUBJECT>Requirement for an IND.</SUBJECT>

    <P>(a) A sponsor shall submit an IND to FDA if the sponsor intends to conduct <PRTPAGE P="63"/>a clinical investigation with an investigational new drug that is subject to § 312.2(a).</P>
    <P>(b) A sponsor shall not begin a clinical investigation subject to § 312.2(a) until the investigation is subject to an IND which is in effect in accordance with § 312.40.</P>
    <P>(c) A sponsor shall submit a separate IND for any clinical investigation involving an exception from informed consent under § 50.24 of this chapter. Such a clinical investigation is not permitted to proceed without the prior written authorization from FDA. FDA shall provide a written determination 30 days after FDA receives the IND or earlier.</P>
    <CITA>[52 FR 8831, Mar. 19, 1987, as amended at 61 FR 51529, Oct. 2, 1996; 62 FR 32479, June 16, 1997]</CITA>
  </SECTION>
</CFRGRANULE>
